Objetivo: pacientes que apresentam a síndrome da resposta inflamatória sistêmica (SIRS) constituem um grupo suscetível a níveis elevados de estresse oxidativo. O objetivo do presente estudo é avaliar o estado de estresse oxidativo e os níveis séricos de retinol e β-caroteno nesses pacientes. Métodos: quarenta e seis pacientes foram divididos em dois grupos: aqueles sem dieta (G1; n = 18) e aqueles com suporte nutricional enteral (G2, n = 28). Foram investigadas as concentrações séricas de retinol e carotenoides totais, proteína C reativa, estresse oxidativo e escore Apache. O estresse oxidativo foi avaliado por dosagem da peroxidação lipídica e estimado por meio da dosagem de TBARS (substâncias reativas ao ácido tiobarbitúrico). Resultados: a média de idade dos pacientes foi de 66,9 (±19,3). Baixas concentrações de retinol e carotenoides foram encontradas em 68,6 e 66,7% do G1, respectivamente. No G2, a concentração sérica média de vitamina A foi de 8078 (± 4035), e o retinol e o β-caroteno apresentaram percentual de inadequação de 31,2 e 33,4%, respectivamente. Não foi observada nenhuma diferença entre os dois grupos, de acordo com as variáveis estudadas, com exceção do PCR e do β-caroteno (p=0,002; p=0,01). Conclusão: os dados apresentados neste estudo indicam a necessidade de estabelecer/rever práticas clínicas no tratamento de pacientes com SIRS, tendo em conta o papel desse micronutriente no sistema imunológico e na defesa antioxidante, sem que isso interfira na sua toxicidade.

Objective: patients suffering systemic inflammatory response syndrome (SIRS) constitute a group susceptible to elevated levels of oxidative stress. This study’s aim is to evaluate the state of oxidative stress and levels of serum retinol and β-carotene in these patients. Methods: forty-six patients were divided into 2 groups: those those without diet (G1; n=18) and those with enteral nutritional support (G2; n=28). Serum levels of retinol and total carotenoids were measured. C-reactive protein (CRP) levels and Apache scores were also calculated. Oxidative stress was estimated by measuring thiobarbituric acid reactive substance (TBARS) levels. Results: the patients’ median age was 66.9 (SD=19.3) years. Lower concentrations of retinol and carotenoids were found in 68.6 and 66.7% of G1, respectively. In G2, despite average vitamin A levels being 8078 + 4035, retinol and β-carotene were considered insufficient (31.2 and 33.4%, respectively). No difference was noted between the 2 groups, according to the variables studied, with the exception being PCR and β-carotene (p=0.002; p=0.01). Conclusion: the data presented in this study supports the need to establish/revise clinical practices in treating SIRS patients, in light of this micronutrient’s role in the immune system and antioxidant defense without it interfering with its toxicity.

Objetivo Avaliar os valores de PSA nadir (PSAn) dois anos após braquiterapia e sua relação com a taxa de recidiva bioquímica. Materiais e Métodos Cento e vinte pacientes foram tratados no período de janeiro de 1998 a agosto de 2007. Todos os pacientes foram submetidos a braquiterapia isolada. Os resultados foram analisados com base na definição de recidiva bioquímica do Consenso Phoenix. Resultados Oitenta e seis pacientes (71,7%) tiveram controle bioquímico e 34 (28,3%) apresentaram recidiva bioquímica. O PSAn médio foi 0,53 ng/ml. O seguimento médio foi 98 meses. Os pacientes foram divididos em dois grupos: grupo 1, com PSAn < 0,5 ng/ml dois anos após a braquiterapia (74 pacientes; 61,7%), e grupo 2, com PSAn ≥ 0,5 ng/ml dois anos após a braquiterapia (46 pacientes; 38, 3%). O grupo 1 teve recidiva bioquímica em 15 pacientes (20,3%) e o grupo 2 em 19 pacientes (43,2%) (p < 0,02). A análise da sobrevida livre de doença bioquímica de sete anos, estratificada pelos dois grupos, apresentou valores de 80% e 64% (p < 0,02), respectivamente. Conclusão Os níveis de PSAn ≥ 0,5 ng/ml dois anos após a braquiterapia estão fortemente correlacionados com mau prognóstico. Este fato pode ajudar a identificar pacientes com risco de recidiva da doença.

Objective To evaluate the relationship between two year PSA nadir (PSAn) after brachytherapy and biochemical recurrence rates in prostate cancer patients. Materials and Methods In the period from January 1998 to August 2007, 120 patients were treated with iodine-125 brachytherapy alone. The results analysis was based on the definition of biochemical recurrence according to the Phoenix Consensus. Results Biochemical control was observed in 86 patients (71.7%), and biochemical recurrence, in 34 (28.3%). Mean PSAn was 0.53 ng/ml. The mean follow-up was 98 months. The patients were divided into two groups: group 1, with two year PSAn < 0.5 ng/ml after brachytherapy (74 patients; 61.7%), and group 2, with two year PSAn ≥ 0.5 ng/ml after brachytherapy (46 patients; 38.3%). Group 1 presented biochemical recurrence in 15 patients (20.3%), and group 2, in 19 patients (43.2%) (p < 0.02). The analysis of biochemical disease-free survival at seven years, stratified by the two groups, showed values of 80% and 64% (p < 0.02), respectively. Conclusion Levels of two year PSAn ≥ 0.5 ng/ml after brachytherapy are strongly correlated with a poor prognosis. This fact may help to identify patients at risk for disease recurrence.

Introduction: Several adverse effects of radiotherapy have been associated with the process of increased oxidative stress in the organism. In this context, vitamin A noteworthy for its important role in combating oxidative stress, in addition to its chemoprotective effect. Objective: To assess the serum levels of vitamin A (retinol and β-carotene) and their relationship to breast cancer staging in patients before and after radiotherapy. Methods: This is a prospective study of women with breast cancer who were evaluated from October 2011 to September 2012 before (T0) and after radiotherapy (T1-7 days). Serum retinol and β-carotene levels were analyzed using High Performance Liquid Chromatography. The assignment of breast cancer stages was based on the classification of malignant tumors that has been proposed by the International Union Against Cancer. Results: 230 patients (mean age 63.6 years, SD ± 9.38) were evaluated. There was a significant reduction in the serum retinol (45.1 ± 18.2 μg/dL at T0 to 27.1 ± 11.7 μg/dL at T1, p < 0.001) and β-carotene (209.0 ± 153.6 μg/L at T0 to 47.7 ± 25.5 μg/L at T1, p < 0.001). There was also a significant difference in serum retinol (p < 0.001) and β-carotene (p = 0.003) levels based on the disease stage. Conclusions: It is recommended the early establishment of adequation serum concentrations of retinol and beta-carotene, offering nutritional assistance for those patients with deficiencies, in order to minimize the harmful effects of radiation.

Introducción: Varios efectos adversos de la radioterapia se han asociado con el proceso de aumento de estrés oxidativo en el organismo. En este contexto, la vitamina A se destaca por su papel importante en la lucha contra el estrés oxidativo, además de su efecto quimioprotector. Objetivo: Evaluar los niveles séricos de la vitamina A (retinol y β-caroteno) y su relación con la estadificación del cáncer de mama en pacientes antes y después de la radioterapia. Métodos: Se realizó un estudio prospectivo de mujeres con cáncer de mama que fueron evaluadas desde octubre 2011 a septiembre 2012 antes (T0) y después de la radioterapia (T1-7 días). Retinol sérico y los niveles de β-caroteno se analizaron mediante cromatografía líquida de alto rendimiento. La asignación de las etapas del cáncer de mama se basa en la clasificación de los tumores malignos que se han propuesto por la Unión Internacional contra el Cáncer. Resultados: 230 pacientes (edad media de 63,6 años, SD + 9,38) fueron evaluados. Hubo una reducción significativa en el retinol sérico (45.1 ± 18.2 μg/dL en T0 a 27.1 ± 11.7 μg/dL en T1, p < 0.001) y β-caroteno (209.0 ± 153.6 μg/L en T0 a 47.7 ± 25.5 μg/L en T1, p < 0.001). También hubo una diferencia significativa en el retinol sérico (p < 0,001) y los niveles de β-caroteno (p = 0,003) sobre la base de la etapa de la enfermedad. Conclusiones: Se recomienda el pronto establecimiento de la adecuación de las concentraciones séricas de retinol y beta-caroteno, ofreciendo asistencia nutricional para los pacientes con deficiencias, con el fin de minimizar los efectos nocivos de la radiación.

Introduction: Critical patients present systemic inflammatory process that can be followed by decrease in plasma concentrations of antioxidant vitamins. Objetive: The aim of this study was to evaluate the effect of the supplementation of antioxidant vitamins in critical patients and their relation with lipid peroxidation. Methods: 23 patients went on a standard diet (G1) and 11 went on a diet with daily supplementation of 10,000 IU of vitamin A, 400 mg of vitamin E and 600 mg of vitamin C (G2). The APACHE II score was made. Serum concentrations of retinol, β-carotene, vitamins C and E, malon-dialdehyde (MDA) and C-reactive protein was measured before (T0) and on the 8th day after the beginning of the nutritional therapy (T1). The groups had been monitored on T0, T1 and T2, (at discharges or death) on the following parameters: mechanical ventilation; hospitalization days; mortality; infection incidence. Results: Serum concentrations of MDA and vitamin E were significantly lower in G2 after intervention and strong tendency to increase vitamin C. There were not significant differences between the groups regarding the clinical parameters. Conclusions: The doses of vitamin A, C and E that were indicated were effective for the current lipid peroxidation reduction.

Introducción: Los pacientes críticos presentan un proceso inflamatorio sistémico que puede seguirse por un descenso en las concentraciones plasmáticas de vitaminas antioxidantes. Objetivo: El objetivo de este estudio fue evaluar el efecto de la suplementación de vitaminas antioxidantes en los pacientes críticos y su relación con la peroxidación lipídica. Métodos: 23 pacientes realizaron una dieta estándar (G1) y 11 una dieta con suplementación diaria de 10.000 UI de vitamina A, 400 mg of vitamina E y 600 mg de vitamina C (G2). Se realizó la puntuación APACHE II. Las concentraciones séricas de retinol, alfa-caroteno, vitaminas C y E, malondialdehído (MDA) y proteína C reactiva se midieron antes (T0) y al octavo día de comenzar con la terapia nutricional (T1). Se monitorizaron los siguientes parámetros en los grupos en T0, T1 y T2, (en el momento del alta o del fallecimiento): ventilación mecánica; días de hospitalización; mortalidad; incidencia de infección. Resultados: Las concentraciones séricas de MDA y vitamina E fueron significativamente menores en el grupo G2 tras la intervención con una fuerte tendencia a aumentar la vitamina C. No hubo diferencias significativas entre los grupos con respecto a los parámetros clínicos. Conclusiones: Las dosis de vitaminas A, C y E que se indicaron fueron eficaces en la reducción actual de la peroxidación lipídica.

OBJETIVO: Avaliar as terapias utilizadas em nossa instituição no tratamento dos sarcomas de extremidades de alto grau, mediante análise da sobrevida global do tratamento multidisciplinar. MATERIAIS E MÉTODOS: Estudo retrospectivo com 36 pacientes, no período de 1993 a 2007, em estádios IIb/III, submetidos a radioterapia externa após cirurgia com ou sem reforço de dose com braquiterapia. RESULTADOS: Trinta e seis pacientes foram submetidos a tratamento cirúrgico seguido de radioterapia externa, sendo que quatro pacientes (11%) receberam reforço de dose com braquiterapia e sete pacientes (19%) receberam quimioterapia. A dose mediana de radioterapia foi de 50 Gy (IC95%: 47-53 Gy), sendo realizado reforço de dose em quatro pacientes com braquiterapia, com dose variando de 16,2-35 Gy. A quimioterapia foi indicada em sete pacientes (19%) com margens positivas. Quinze pacientes apresentaram recidiva local e/ou a distância (42%) e todos faleceram. Vinte e um pacientes (58%) encontram-se sem evidência clínica e radiológica de recidiva local e/ou a distância. O seguimento mediano é de 88 meses (IC95%: 74-102). A taxa de sobrevida global para sete anos foi de 80%. CONCLUSÃO: Concluímos que a associação cirurgia + radioterapia apresenta-se como tratamento eficaz e com ótimas respostas e melhora da sobrevida global na possibilidade de associação da braquiterapia.

OBJECTIVE: To evaluate the therapies utilized in the authors' institution for management of high-grade extremity sarcomas, analyzing the overall survival rates following multidisciplinary treatment. MATERIALS AND METHODS: Retrospective study developed in the period from 1993 to 2007 with 36 patients diagnosed with stages IIb/III, submitted to postoperative external beam radiotherapy, with or without boost dose, utilizing high-dose brachytherapy. RESULTS: Thirty-six patients underwent surgery followed by adjuvant external beam radiation therapy. Four patients (11%) received boost dose with brachytherapy, and seven (19%) received chemotherapy. The average dose for radiotherapy was 50 Gy (CI 95%: 47-53 Gy), and the four patients with brachytherapy boost received doses ranging from 16.2 to 35 Gy. Chemotherapy was indicated for seven patients (19%) with positive margins. Fifteen patients (42%) presented local or distant recurrence, and all of them progressed to death. Twenty-one patients (58%) remain with no clinical/radiological evidence of local/distant recurrence. The mean follow-up time was 88 months (IC 95%: 74-102). The overall seven-year survival rate was 80%. CONCLUSION: Combined surgery and radiotherapy is an effective treatment with excellent outcomes in cases where brachytherapy is associated, with improved overall survival rates.

Objectives: To assess the incidence and clinical parameters that could influence migration of seeds in localized prostate cancer patients treated by stranded versus loose sources by Iodine-125 brachytherapy. Material and Methods: 100 patients were treated from January/1998 until December/2006. Age, PSA, clinical stage, Gleason, prostate volume, number of seeds, activity of radioactive seeds, and dosimetric parameters, such as V100, V150 and D90 were evaluated. Results: Mean follow-up was 79 months (18 - 120. CI 95%: 72 - 85). Overall, 6 of 100 patients experienced seed migration. Seed migration was found in 4/50 (8%) patients using loose seeds and in 2/50 (4%) treated by stranded seeds. Mean value dosimetric parameters for stranded seeds were greater than those for loose seeds (V100(%): 88.7/82, D90(Gy): 149.2/140.3, D90(%): 104.2/93.8, V150 (%): 53.8/47, respectively). No significant difference in migration of seeds was detected between loose and stranded seeds considering age (p = 0.33), PSA (p = 0.391), prostate volume (p = 0.397), activity of radioactive seeds (p = 0.109), number of seeds (p = 0.338), V100 (p = 0.332), although significant differences were measured in the values of D90(% and Gy) (p = 0.022 and 0.011) and V150 (p = 0.023). Conclusions: Seed migration after brachytherapy might occur and it does affect post-implant dosimetry.

OBJECTIVE: To report the seven-year preliminary results of a single-center on brachytherapy with Iodine-125 seeds, used in combination with external beam radiotherapy in selected patients with localized prostate cancer (T1-T2). MATERIALS AND METHODS: All 105 patients treated by brachytherapy with Iodine-125 seeds, from January/1998 to December/2004, were retrospectively analyzed. The prescribed dose was 144 Gy at the periphery of the prostate for isolated brachytherapy, and 110 Gy for the combination with external beam radiotherapy. The external beam radiotherapy dose was 45 Gy, at the prostatic bed. Neoadjuvant hormone therapy was indicated for selected patients, who received luteinizing hormone-releasing hormone (LH-RH) and/or antiandrogens. For definition of biochemical relapse, it was adopted the American Society for Therapeutic Radiology and Oncology consensus. RESULTS: Of the 105 patients treated, 90 were followed for a mean period of 70 months. Biochemical disease control was achieved in 62 (69%) and biochemical recurrence was manifested in 28 (31%). The analysis of each risk group showed biochemical disease control rates of 79%, 71% and 52% in the low, intermediate and high risk groups, respectively. The mean time for biochemical recurrence was 22 months. Genitourinary acute toxicity was classified as grade 0-2 (RTOG) in 88.5% and in 94.2% for the late toxicity (RTOG/EORTC). Gastrointestinal acute toxicity was graded as 0-2 (RTOG) in 100% and in 97.7% for the late morbidity. No grade 5 was detected. CONCLUSIONS: Brachytherapy with Iodine-125 seeds is an effective alternative treatment for early stage prostatic cancer, with good biochemical disease control rates and low to moderate toxicity. The best results were obtained in low and intermediate risk patients.